NEW GAMMA KNIFE CENTER IN LISBON, PORTUGAL, ORDERS LEKSELL GAMMA KNIFE® PERFEXION™ FROM ELEKTA

NEW GAMMA KNIFE CENTER IN LISBON, PORTUGAL, ORDERS LEKSELL GAMMA KNIFE®
PERFEXION™ FROM ELEKTA

PRESS RELEASE	
Stockholm, Sweden, May 10, 2007

Elekta today announced an order for Leksell Gamma Knife® Perfexion™, the latest
and most advanced system ever for non-invasive radiosurgery of brain disorders,
from Centro Gamma Knife Radiocirurgia S.A. This first Gamma Knife Center in
Portugal will be established at Hospital CUF Infante Santo, a part of the Jose
Mello-Saude Group.

Centro Gamma Knife Radiocirurgia S.A. (CGKR) is a private initiative,
established with the aim to bring this non-invasive, innovative technology to
patients in Portugal. Leksell Gamma Knife Perfexion, scheduled to be in clinical
operation by early fall 2007, will be installed in a new Gamma Knife Center that
will be managed by CGKR together with Hospital CUF Infante Santo in Lisbon.

Hospital CUF Infante Santo is a well equipped private hospital with a long
tradition and reputation for excellence in health care. The hospital is
centrally located in Lisbon and the Gamma Knife Center will treat patients both
from Portugal and from other countries. 

“We are very pleased that we have been able to bring this amazing technology for
non-invasive radiosurgery of brain disorders to Portugal. The creation of the
new Gamma Knife Center at Hospital CUF Infante Santo will be a benefit for
patients from the whole country,” said Pedro Lucena e Valle, Chief Operating
Officer at CUF. “We are very impressed with the performance of Leksell Gamma
Knife Perfexion as has been shown by our colleagues in Marseille, France. With
unlimited cranial reach and ability to also treat the cervical spine, we will be
able to address malignant and benign brain tumors as well as other brain
disorders with extreme precision and accuracy, giving patients a much less
traumatic alternative to invasive surgery”, ends Mr. Lucena e Valle. 

Gamma Knife® surgery, also known as stereotactic radiosurgery, is a method for
treating tumors and other brain disorders with ultra precise focused radiation,
in many cases eliminating the need for invasive procedures. Contrary to invasive
brain surgery, requiring many days of aftercare in the hospital, the patient
normally leaves the hospital the same day and can return to normal life on the
following day. 

Leksell Gamma Knife Perfexion is a technological breakthrough incorporating a
completely new and optimized design that will improve and expand Gamma Knife
surgery while maintaining full clinical compatibility with Gamma Knife
procedures and protocols based on over 400,000 treated patients. 

The patented collimator design provides the neurosurgeon or radiation oncologist
with almost unlimited ability for sculpting the dose to produce complex dose
distributions with incomparable accuracy. Designed from the ground up with
patient and staff comfort in mind, the high degree of automation offered by
Leksell Gamma Knife Perfexion reduces treatment times to a minimum. 

******

For further information, please contact:

Peter Ejemyr, Group VP Corporate Communications, Elekta AB
Tel: +46 733 611 000 (mobile), e-mail: peter.ejemyr@elekta.com  

About Elekta

Elekta is an international medical-technology Group, providing meaningful
clinical solutions, comprehensive information systems and services for improved
cancer care and management of brain disorders. All of Elekta's solutions employ
non-invasive or minimally invasive techniques and are therefore clinically
effective, gentle on the patient and cost-effective. 

Clinical solutions include among others Leksell Gamma Knife® for non-invasive
treatment of brain disorders and Elekta Synergy® for image guided radiation
therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April
2005, the Elekta Group is the world's largest supplier of oncology software. 

Elekta's systems and solutions are used at over 4,000 hospitals around the world
to treat cancer and manage clinical operations as well as to diagnose and treat
brain disorders, including tumors, vascular malformations and functional
disorders. 

With approx. 2,000 employees, Elekta's corporate headquarter is located in
Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com.